Status:
RECRUITING
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Lead Sponsor:
Capital Medical University
Conditions:
Locally Advanced Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main o...
Eligibility Criteria
Inclusion
- Adult research participants, aged over 18 years old;
- Non small cell lung cancer that requires pathological confirmation;
- All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3);
- ECOG physical condition is 0-2;
- In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment.
Exclusion
- Prisoners who are not convenient for close clinical follow-up;
- Study participants with contraindications to radiation therapy.
Key Trial Info
Start Date :
February 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
911 Patients enrolled
Trial Details
Trial ID
NCT07164885
Start Date
February 17 2025
End Date
December 30 2027
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Hong Kong Shenzhen Hospital
Shenzhen, Guangdong, China, 518000